Aprea Therapeutics, Inc. (NASDAQ:APRE) CEO Acquires $10,120.00 in Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE) CEO Oren Gilad purchased 5,500 shares of the business’s stock in a transaction on Thursday, April 3rd. The shares were bought at an average cost of $1.84 per share, for a total transaction of $10,120.00. Following the purchase, the chief executive officer now owns 345,620 shares of the company’s stock, valued at $635,940.80. This trade represents a 1.62 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Aprea Therapeutics Price Performance

NASDAQ APRE traded up $0.04 during mid-day trading on Friday, hitting $1.84. The company’s stock had a trading volume of 5,897 shares, compared to its average volume of 19,330. The firm has a market capitalization of $10.08 million, a P/E ratio of -0.65 and a beta of 1.04. Aprea Therapeutics, Inc. has a 52-week low of $1.74 and a 52-week high of $6.48. The stock’s fifty day simple moving average is $2.86 and its two-hundred day simple moving average is $3.20.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Tuesday, March 25th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.20. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.15 million. On average, equities analysts forecast that Aprea Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on APRE. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research report on Wednesday, January 15th. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, March 25th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Stonepine Capital Management LLC grew its stake in shares of Aprea Therapeutics by 8.8% in the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after buying an additional 12,047 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Aprea Therapeutics during the 4th quarter worth approximately $43,000. LPL Financial LLC purchased a new position in Aprea Therapeutics in the 4th quarter worth approximately $53,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Aprea Therapeutics in the fourth quarter valued at approximately $116,000. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.